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A major responsibility of the National
Toxicology Program (NTP) is to investigate the
potential toxic and carcinogenic effects of vari-
ous chemicals. Studies conducted by the NTP
are used by the U.S. Environmental Protection
Agency, the Food and Drug Administration,
and other federal and state agencies in their
consideration of regulations and policies for
protecting public health. The 2-year rodent
cancer bioassay is an important component of
the NTP’s investigations; these bioassays typi-
cally involve groups of male and female mice
and rats randomly assigned to either a control
group or one of three dose groups (low,
medium, and high). At death, each animal is
extensively examined for microscopic and
macroscopic tumors, as well as for abnormal
changes in tissues. Of particular interest is
whether the rate of occurrence of a specific
tumor is related to dose.
Because some animals do not survive to
the end of the 2-year study, the NTP’s statisti-
cal analyses of site-speciﬁc tumor rates employ
a survival-adjusted, continuity-corrected
Cochran-Armitage (CA) trend test, the poly-3
trend test (Armitage 1955; Bailer and Portier
1988; Cochran 1954; Portier and Bailer
1989). For simplicity, in this article we refer to
this test as the NTP trend test. Typically, this
trend test is followed by pairwise comparisons
of each dose group with the control group.
It is important to distinguish between two
types of parameters related to the problem of
current interest, namely, age-specific tumor
incidence rate and lifetime tumor rate. The for-
mer is the hazard rate associated with the age at
tumor onset, and the latter is the expected pro-
portion of animals that ever develop a tumor
(at any age), which is a function of both the
tumor incidence rate and the mortality rate.
Thus, depending on mortality patterns, life-
time rates generally will not correspond
exactly with age-speciﬁc incidence rates. The
age-speciﬁc incidence rate is a more meaning-
ful, but less accessible, end point than is the
lifetime rate. For simplicity of notation, we
have dropped “age-specific” from the phrase
“age-speciﬁc tumor incidence rate.”
All point estimators discussed in this article
and in other reports, such as Bailer and Portier
(1988) and Peddada et al. (2005), estimate
lifetime tumor rates. Further, trend tests such
as the NTP trend test, the trend test developed
by Peddada et al. (2005), and the trend test
proposed in this article use survival-adjusted
lifetime tumor rates to test for trends in tumor
incidence rate. Simulation studies performed
by Dinse (1991) and Peddada et al. (2005)
and in this article suggest that, although these
tests employ lifetime tumor rates rather than
tumor incidence rates, they also provide valid
inferences about tumor incidence rates.
Although tumor incidence rates may
strictly increase with dose, lifetime tumor
rates may have an umbrella-shaped or a
plateau-shaped dose–response curve because
of higher mortality in the upper dose groups.
An umbrella or plateau-shaped response curve
for lifetime tumor rate is also likely to occur if
the tumor incidence rate has a plateau-shaped
dose–response curve. In such situations, the
NTP trend test may not be sensitive enough to
detect this dose-related response because it is
based on linear regression of the estimated life-
time tumor rate on dose. For example, in a
study of the chemical isoprene, female rats
were exposed to 0, 220, 700, or 7,000 ppm
isoprene by inhalation for 2 years (NTP 1999).
Mammary gland fibroadenomas occurred in
19, 35, 32, and 32 of 50 animals, respectively.
Survival did not differ among dose groups, and
the survival-adjusted lifetime tumor rates were
44%, 74%, 74%, and 73%, respectively. The
NTP trend test yielded a p-value of 0.11.
However, each of the pairwise comparisons
with the control group was significant at
p < 0.002 (NTP 1999). Data such as these are
not uncommon in NTP studies, and in these
situations the NTP trend test may fail to detect
a signiﬁcant chemical effect.
Motivated by such examples, Peddada et al.
(2005) developed an order-restricted inference-
based procedure that is well suited for non-
linear responses. Simulation studies suggest that
this isotonic regression-based test performs bet-
ter than does the NTP trend test when the
tumor rates increase nonlinearly in dose
(Peddada et al. 2005). However, this test may
have less power than the NTP trend test when
the tumor response increases linearly with dose.
Therefore, in this article we propose a new test
that modifies their isotonic regression-based
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In rodent cancer bioassays, groups of animals are exposed to different doses of a chemical of
interest and followed for tumor occurrence. The resulting tumor rates are commonly analyzed
using a survival-adjusted Cochran-Armitage (CA) trend test. The CA trend test has reasonable
power when the tumor-response curve is linear in dose, but it may be underpowered for a non-
linear response. An alternative survival-adjusted test procedure based on isotonic regression
methodology has previously been proposed. Although this alternative procedure performs well
when the tumor response is nonlinear in dose, it has less power than the CA trend test when the
response is linear in dose. Here, we introduce a new survival-adjusted test procedure that makes
use of both the CA trend test and the isotonic regression-based trend test. Using a broad range
of experimental conditions typical of National Toxicology Program (NTP) bioassays, we con-
ducted extensive computer simulations to compare the false-positive error rate and power of the
proposed procedure with the survival-adjusted CA trend test. The new procedure competes well
with the survival-adjusted CA trend test when observed tumor rates are linear in dose and per-
forms substantially better when observed tumor rates are nonlinear in dose. Further, the proposed
trend test almost always has a smaller false-positive rate than does the survival-adjusted CA trend
test. We also developed an order-restricted inference-based procedure for performing multiple
pairwise comparisons between each of the dose groups and the control group. The trend test and
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[Online 10 November 2005]test. Based on our extensive simulations, the
resulting test competes well with the NTP
trend test for strictly linear dose–response pat-
terns and performs better than the NTP trend
test for nonlinear dose–response patterns.
In addition to testing for dose-related
trends, NTP performs pairwise comparisons
between each of the dose groups and the con-
trol group, with particular attention paid to the
medium- and high-dose groups. Currently, no
adjustment is made for multiple comparisons.
Consequently, the NTP’s pairwise comparison
tests are subject to false-positive rates that
exceed the nominal 0.05 level. Using the
order-restricted inference methodology devel-
oped in Hwang and Peddada (1994) and
Peddada et al. (2001), we introduce a new
pairwise comparison procedure that controls
the overall false-positive rate.
Materials and Methods
Suppose there are K dose groups with doses
0=d1 < d2 < . . . < dK with ni animals assigned
to the ith dose group, i = 1, 2, . . . , K. We
denote the tumor status at necropsy of the jth
animal in the ith dose group by yij, where yij =1
if the animal has a speciﬁc tumor and is 0 other-
wise. To compute the poly-3 survival-adjusted
sample size for the ith group (Bailer and Portier
1988; Portier and Bailer 1989), we deﬁne ani-
mal-speciﬁc weights wij = 1 if the jth animal had
a tumor at necropsy, otherwise wij = tij
3 where tij
is the fraction of duration of the study for which
the animal survived. For the ith dose group, the
poly-3 survival-adjusted sample size is 
and the poly-3 survival-adjusted estimator for
the lifetime tumor rate, πi, is 
Test for an increasing trend in dose. The
poly-3 survival-adjusted CA trend test statistic is
[1]
where, for i = 1, 2, . . . , K, 
Furthermore,
Note that S 2 is a jackknife variance estimator
introduced in Bieler and Williams (1993).
Performance of the above trend statistic was
evaluated by Peddada et al. (2005).
The NTP uses a continuity-corrected
poly-3 trend test statistic, deﬁned as
[2]
where
[3]
The null hypothesis of no chemical effect
on tumor incidence is rejected in favor of the
alternative that there is a positive trend in dose
if A > 0 and T1 exceeds the (1– α)th percentile
of a standard normal distribution.
As an alternative to the poly-3 survival-
adjusted CA trend test statistic, Peddada et al.
(2005) introduced the following trend test
statistic:
[4]
where
[5]
are the isotonized values of π
∧
i under the order
restriction that πi values are nondecreasing
with dose. This statistic performs well in terms
of power when πi values are monotonically,
but nonlinearly, increasing with dose, whereas
the poly-3 survival-adjusted CA trend test per-
forms well when πi values are linearly increas-
ing with dose (Peddada et al. 2005).
Motivated by these observations, we pro-
pose a hybrid statistic that draws on both of
these procedures so that the resulting test sta-
tistic has improved power in all situations;
that is, the proposed statistic is more likely to
detect a dose-related trend, if it exists, than is
the poly-3 survival-adjusted CA trend test.
First, we note that in some instances it is pos-
sible for mortality rates in one or more dose
groups to be substantially higher than in the
control group. In such cases, 
in the denominator of the above test statistic
may inflate the false-positive or type I error
rates. For this reason, we modify the trend
statistic TISO of Peddada et al. (2005) as
[6]
and propose the maximum of the NTP
trend test statistic and the modiﬁed isotonic
regression-based trend statistic,
[7]
as the test statistic for testing a dose-related
nondecreasing trend in tumor incidence rate.
Note that T is the larger of T1, a test statistic
for the linear trend in survival-adjusted pro-
portions, and larger than T2, a test statistic for
the largest difference in survival-adjusted pro-
portions after standardization to a non-
decreasing pattern.
We approximate the distribution of T
under the null hypothesis that there is no dif-
ference in tumor incidence rates among the
dose groups as follows. We generate K inde-
pendent standard normal random deviates,
X1, X2, . . . XK, and compute
[8]
In the above expression, X
^
i, i = 1, 2, . . . , K,
are the “isotonized” values of Xi We approxi-
mate the null distribution of T by simulating
the distribution of max(V1, V2) from which
p-values or critical values for the trend test can
be obtained.
Although all our computations were per-
formed in FORTRAN language, we are in the
process of developing a JAVA-based software
for implementing the methodology introduced
in this article. For additional details regarding
the software, please contact the authors.
Multiple pairwise comparisons with the
control group. In addition to performing a
trend test, scientists at the NTP are often
interested in performing pairwise compari-
sons between each of the dose groups and the
control group. In this situation, the null
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the dose groups are no larger than the rate in
the control group; the alternative hypothesis
is that the tumor incidence rate in at least one
dose group is strictly larger than in the con-
trol group. In order-restricted inference ter-
minology, this alternative hypothesis is
known as simple tree order. Currently, the
NTP performs pairwise comparisons of each
dose group with the control group by apply-
ing test statistic T1 on two groups, the control
group and the particular dose group of inter-
est. Although comparisons are generated
between the control group and each of the
dose groups, NTP researchers are particularly
interested in whether the tumor incidence
rate in either of the top two dose groups
exceeds the rate in the control group. This
approach does not account for multiple com-
parisons between each of the dose groups and
the control group. In the following, we pro-
pose a simple test statistic derived from the
order-restricted inference methodology intro-
duced by Hwang and Peddada (1994) and
used by Peddada et al. (2001).
Using the procedure described by Hwang
and Peddada (1994), lifetime tumor rates for
the dose groups are estimated by π1
≈ = π1
∼ for
the control group, and π1
≈ = max(π1
∼ , π1
∧ ),
i ≥ 2.
To illustrate the above formula, suppose
the poly-3 tumor rates for the four test groups
are π1
∧ = 0.3, π2
∧ = 0.2, π3
∧ = 0.4, π4
∧ = 0.35, with
corresponding poly-3 adjusted sample sizes of
n1
* = 44.2, n2
* = 45.6, n3
* = 40, n4
* = 41, respec-
tively. Then, using the formula (Equation 5)
for π1
∼ we have
[9]
Accordingly, π2
≈ = max(0.249, 0.2) = 0.249,
π3
≈ = max(0.249, 0.4) = 0.4, π2
≈ = max(0.249,
0.35) = 0.35.
To derive the test statistic and its distribu-
tion under the null hypothesis that all dose
groups have the same tumor rates, we first
generate K independent standard normal ran-
dom deviates X1, X2, …, XK. Let
[10]
The proposed test statistic for comparing
the ith dose group with the control group is
[11]
Approximate critical values for R2, R3,
. . ., RK can be obtained from the simulated
distribution of V3. The proposed pairwise
procedure rejects the null hypothesis if
R = max(R2, R3, . . ., RK) exceeds the critical
value derived from the distribution of V3. This
is a nonparametric analogue of Tukey’s hon-
estly signiﬁcant differences post hoc multiple
comparisons procedure commonly applied in
analysis of variance settings.
Results
Simulation study. We conducted an extensive
simulation study to compare the performance
of the proposed trend test, T, with the NTP
trend test. A total of 750 nonnull conﬁgura-
tions and 150 null conﬁgurations, similar to
those commonly encountered in the NTP
rodent bioassays, were simulated. All simula-
tion results reported in this article are based
on 10,000 simulation runs, and the nominal
level of signiﬁcance is α = 0.05.
Simulation parameters were patterned after
the NTP rodent cancer bioassays. We consid-
ered a total of three dose groups (low, medium,
and high) and a control group, with 50 ani-
mals assigned to each group. As described by
other authors (e.g., Dinse 1991; Peddada et al.
2001, 2005), for each animal in the ith dose
group, i = 1, 2, 3, 4, we generated realizations
of two independent Weibull random variables,
Yi1 and Yi2, where Yi1 represented the time to
tumor onset and Yi2 represented the time to
death from natural causes. The survival func-
tion of Yij, i = 1, 2, 3, 4 and j = 1, 2 is given by
P(Yij > t|di) = exp(–ψjφij
ditγj). We simulated
these random variables such that the duration
of the study was 24 months, which is typical of
the NTP rodent bioassays. We simulated two
dose patterns, 2-fold dose spacing and 5-fold
dose spacing, namely, (d1, d2, d3, d4) = (0, 0.5,
1, 2) and (0, 0.1, 0.5, 2.5).
As previously described (Peddada et al.
2005), we considered constant dose effect on
mortality; that is, φi2 = φ2, with patterns of
φ2 = 1 (no effect), 1.5, 2, 2.5, and 3 (severe
effect). We set the mortality shape parameter
at γ2 = 5 and baseline mortality scale parame-
ter at ψ2 = 4.479 × 10–8 so that 70% of the
animals in the control group survived to the
end of the 2-year study, a rate often observed.
The three tumor onset shape parameter
(γ1) values considered in this study were 1.5,
3, and 6. Poly-3 survival adjustments are based
on the assumption that the true tumor onset is
Weibull with shape parameter γ1 = 3 (Portier
and Bailer 1989). Thus, the ideal situation for
the poly-3 survival correction is γ1 = 3. We
considered five different background tumor
rates, π1, ranging from rare (0.001, 0.01,
0.05) to common (0.15, 0.30). Values of the
baseline tumor onset scale parameter, ψ1, cor-
responding to each π1 are given in Table 1.
Finally, we chose six different sets of the effect
of dose on tumor onset, φi1, for each of the
ﬁve background tumor rates; values of φi1 are
given in Table 2. In each case, the null
hypothesis corresponds to the case when the
incidence rates are all equal; that is, the ratios
are (1:1:1:1). Thus, a total of 375 nonnull and
75 null configurations were considered for
each of the two dose spacings.
Results of the simulation study are repre-
sented by scatter plots of false-positive error
rates (or power) with the NTP procedure on
the horizontal axis and the proposed procedure
on the vertical axis. For the trend tests, false-
positive error rates are summarized in Figure 1
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Table 1. Patterns of tumor onset shape parameter (γ1), and tumor onset scale parameter (ψ1) by background
tumor rate (π1).
Background tumor rates (π1)
Variables 0.001 0.01 0.05 0.15 0.30
γ1 = 1.5
ψ1 9 × 10–6 9 × 10–5 4.7 × 10–4 15 × 10–4 33 × 10–4
γ1 = 3
ψ1 8 × 10–8 8 × 10–7 4.2 × 10–6 13.4 × 10–6 29.7 × 10–6
γ1 = 6
ψ1 6.5 × 10–12 6.5 × 10–11 32.5 × 10–11 10.4 × 10–10 23.2 × 10–10
Table 2. Patterns of tumor incidence ratios (φ11:φ21:φ31:φ41) for the four dose groups by background tumor
rate (π1).
Tumor incidence ratio (φ11:φ21:φ31:φ41)
Very rare tumors Somewhat rare tumors Common tumors
Dose–effect set (π1 = 0.001, 0.01) (π1 = 0.05) (π1 = 0.15, 0.30)
1 1:1:1:1 1:1:1:1 1:1:1:1
2 1:1:1:10 1:1:1:4 1:1:1:2
3 1:1:10:10 1:1:4:4 1:1:2:2
4 1:10:10:10 1:4:4:4 1:2:2:2
5 1:5:5:10 1:1.5:1.5:4 1:1.5:1.5:2
6 1:5:10:15 1:2:3:4 1:1.25:1.75:2and powers in Figure 2. For the pairwise com-
parison procedure, false-positive error rates are
summarized in Figure 3. In each case, the diag-
onal line represents the line of equality between
the two tests. The horizontal and vertical lines
in Figures 1 and 3 are drawn at a distance of
0.05 + 1.645√(0.05×0.95)/10,000 from the
origin. In Figures 1 and 3, points falling to the
right of the vertical line indicate instances in
which the NTP procedure exceeds the nominal
level of 0.05, and points falling above the hori-
zontal line correspond to instances in which the
proposed test exceeds the nominal level of 0.05.
In Figure 2, points falling below and to the
right of the diagonal line correspond to
instances in which the NTP trend test has more
power than the proposed trend test, whereas
points falling above and to the left of the diago-
nal line correspond to instances in which the
proposed trend test has more power than the
NTP trend test. To reduce clutter in the plots,
we tested equality of the false-positive error
rates (or power) of the NTP procedure and the
proposed procedure using a two-sample z-test
for proportions, and we plotted only those
points for which there was a signiﬁcant differ-
ence between the NTP test and the proposed
test at the 5% level of signiﬁcance.
For the 75 null patterns considered in this
simulation study, there were 23 patterns
where the two tests had signiﬁcantly different
false-positive error rates (Figure 1). This result
was observed for 2-fold spacing as well as
5-fold spacing. The proposed test was rarely
more liberal than the NTP trend test when
both tests exceeded the nominal level; that is,
the false-positive rate of the proposed test
never exceeded that of the NTP trend test.
Furthermore, the NTP trend test was more
liberal than the proposed test for common
tumors (π1 ≥ 0.15) considered in this study.
Although we only plotted the cases for which
the false-positive error rates of the two tests
differed significantly, the false-positive error
rate of the proposed trend test never exceeded
0.087, and that of the NTP trend test never
exceeded 0.099.
The power of the two tests differed signiﬁ-
cantly in 270 of the 375 nonnull dose patterns
for 2-fold spacing (Figure 2A). In approxi-
mately 70% of these 270 patterns, the pro-
posed trend test had higher power than did the
NTP trend test. Thus, a large number of
points in Figure 2A are above the diagonal line.
Further, in 15 of the 270 patterns (about 6%),
the false-positive error rate of the NTP trend
test exceeded the nominal 0.05 significance
level and was signiﬁcantly higher than that of
the proposed test. These cases are denoted by a
“+” in Figure 2A. The gain in power for the
proposed test was as high as 0.275 (0.69 for
the proposed test vs. 0.415 for the the NTP
trend test), a relative gain of 66%. In contrast,
the best gain observed for the the NTP trend
test was 0.048 (0.502 for the the NTP trend
test vs. 0.454 for the proposed test), a modest
relative gain of < 10%.
The power gains made by the proposed test
were even more substantial for 5-fold dose spac-
ing (Figure 2B). Power of the two tests differed
significantly in 264 of the 375 nonnull pat-
terns, and the proposed test had higher power
in almost 85% of these patterns. Thus, most
points in Figure 2B are above the diagonal.
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Figure 1. Comparison of false-positive error rates for 2-fold dose spacing (A) and 5-fold dose spacing (B).
The false-positive error rate of the proposed trend test was plotted against the false-positive error rate of
the NTP trend test. We plotted only the cases where the two procedures differed signiﬁcantly in terms of
false-positive error rates; results are based on 10,000 simulation runs per conﬁguration. The plot suggests
that the false-positive rate of the proposed test is always less than that of the NTP trend test when both
tests exceed the nominal level.
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fered significantly in terms of false-positive error rates; results are based on 10,000 simulation runs per
conﬁguration. In both (A) and (B), all points are below the horizontal line at 0.054. This suggests that the
false-positive rate of the proposed procedure is almost always less than that of NTP pairwise procedure
and never exceeds the nominal 0.05 signiﬁcance level.
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proposed test is notFurther, as we observed with the 2-fold dose
spacing, in 13 of the 264 patterns (about 5%)
the false-positive error rate of the the NTP
trend test exceeded the nominal 0.05 signiﬁ-
cance level and was significantly higher than
that of the proposed test. As in Figure 2A, these
cases are denoted by a “+.” The gain in power
for the proposed test was as high as 0.460
(0.671 for the proposed test vs. 0.211 for the
NTP trend test), > 300%. In contrast, the best
gain observed for the NTP trend test was 0.038
(0.331 for the NTP trend test vs. 0.293 for the
proposed test), a modest relative gain of < 12%.
In cases for which tumor incidence rates
increased monotonically, but not linearly, with
dose, the proposed trend test performed better
than the NTP trend test in terms of both power
and false-positive error rate. As expected, the
NTP trend test performed better than the pro-
posed test in cases for which tumor incidence
rates increased linearly with dose. But even in
such cases, the gains made by the NTP trend
test were modest. Furthermore, the false-posi-
tive error rate of the NTP trend test often
exceeded the nominal 0.05 signiﬁcance level.
For the null configurations described
above, we also compared false-positive error
rates of the proposed pairwise comparisons
procedure with the NTP procedure for pair-
wise comparisons between the medium- and
high-dose groups with the control group.
Figure 3 shows that the proposed method
maintained false-positive error rates at or
below the nominal 0.05 level, whereas the
NTP procedure was often liberal, exceeding
the nominal level of 0.05. Although we plot-
ted only the cases in which the false-positive
error rates of the two tests differed signifi-
cantly, the proposed pairwise test never
exceeded 0.05, whereas the NTP pairwise test
had false-positive error rates as high as 0.11.
An NTP example. As part of an NTP
bioassay on isoprene, female F344/N rats were
exposed to isoprene for 2 years through
inhalation (NTP 1999). Isoprene is a naturally
occurring compound in plants, as well as a by-
product of ethylene production. It is similar in
structure to 1,3-butadiene, a potent rodent
carcinogen.
Fifty female rats were exposed to 0, 220,
700, or 7,000 ppm isoprene; 19, 35, 32, and
32, respectively, developed mammary gland
ﬁbroadenomas. Survival-adjusted tumor pro-
portions showed a plateau-shaped response,
with 44%, 74%, 74%, and 73%, respectively,
of the animals developing ﬁbroadenomas. The
NTP trend test gave a p-value of 0.105,
whereas each dosed group differed from the
control group at p < 0.002. Because of the
wide dose spacing and the plateau-shaped
response beginning at the low dose of
220 ppm, the NTP trend test was not sensitive
enough to detect the dose-related response.
The proposed trend test provided a
significant dose-related trend in mammary
gland fibroadenomas with a p-value of
0.0014. As indicated in our simulation study
discussed above, this statistic is capable of
detecting monotonic nonlinear trends with
dose and is not affected by wide dose spacing.
Furthermore, using the proposed method for
pairwise comparisons, each dose group differs
from the control group at p < 0.005. From
our simulations, we can be confident that,
among all of the pairwise comparisons with
the control group, the overall false-positive
rate of 0.05 is not exceeded.
Discussion
We have presented a trend test for tumor inci-
dence data that takes advantage of the
strengths of the CA trend test when the dose–
response relationship is linear and also takes
advantage of strengths of nonparametric
order-restricted methods when the dose–
response relationship is monotonic but non-
linear. Most important, the false-positive rate
of the proposed test rarely exceeds that of the
NTP trend test when both tests exceed the
nominal level, yet in many instances the pro-
posed test outperforms the NTP trend test in
terms of power. Further, we have also pro-
vided a simple procedure for performing pair-
wise comparisons between each of the dose
groups and the control group;, this procedure
controls the overall false-positive error rates
when conducting multiple tests.
Because NTP rodent bioassay data are
used by federal and state agencies to assist in
formulating regulatory policies, it is crucial
for the statistical methods to be powerful
enough to detect dose-related trends when
they exist. Equally important, these methods
should not produce excessive false-positive
ﬁndings. The trend test and the multiple com-
parisons procedure that we have proposed here
make important steps in both directions.
When dose–response relationships are mono-
tonic but nonlinear, the proposed trend test is
more powerful than is the NTP trend test.
Although both trend tests can exceed the
nominal 0.05 level under some circumstances,
the false-positive error rate of the proposed
trend test is almost always less than that of the
NTP trend test when both tests exceed the
nominal level. Therefore, the occurrences of
false positives will be reduced with use of the
proposed trend test. Furthermore, the NTP
pairwise comparisons method does not correct
for multiple comparisons and often exceeds
the nominal 0.05 level in pairwise compar-
isons of each of the dose groups to the control
group, particularly for common tumors. The
proposed pairwise comparisons method con-
trols the false-positive rate so that it stays near
(or less than) 0.05 under a wide range of situa-
tions that we commonly encounter in NTP
studies. Thus, these proposed methods should
provide more accurate decisions about the
potential carcinogenic effects of chemicals.
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